- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00676052
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Multicentre Dose Ranging Study for Once Daily GSK233705 in COPD
Přehled studie
Postavení
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Tucuman, Argentina, 4000
- GSK Investigational Site
-
-
Buenos Aires
-
La Plata, Buenos Aires, Argentina, CP1900
- GSK Investigational Site
-
Mar del Plata, Buenos Aires, Argentina, B7600FZN
- GSK Investigational Site
-
Mar del Plata, Buenos Aires, Argentina, 7600
- GSK Investigational Site
-
Pergamino, Buenos Aires, Argentina, 2700
- GSK Investigational Site
-
-
-
-
-
Dimitrovgrad, Bulharsko, 6400
- GSK Investigational Site
-
Ruse, Bulharsko, 7000
- GSK Investigational Site
-
Sofia, Bulharsko, 1431
- GSK Investigational Site
-
Sofia, Bulharsko
- GSK Investigational Site
-
-
-
-
-
Santiago, Chile, 8380453
- GSK Investigational Site
-
-
Región Metro De Santiago
-
Santiago, Región Metro De Santiago, Chile, 7500551
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile
- GSK Investigational Site
-
Santiago, Región Metro De Santiago, Chile, 7500691
- GSK Investigational Site
-
-
Valparaíso
-
Valparaiso, Valparaíso, Chile, 2341131
- GSK Investigational Site
-
-
-
-
-
Cavite, Filipíny, 4114
- GSK Investigational Site
-
Quezon City, Filipíny, 1100
- GSK Investigational Site
-
Quezon City, Filipíny, 1109
- GSK Investigational Site
-
-
-
-
-
Almelo, Holandsko, 7609 PP
- GSK Investigational Site
-
Eindhoven, Holandsko, 5623 EJ
- GSK Investigational Site
-
Hoofddorp, Holandsko, 2134 TM
- GSK Investigational Site
-
Hoorn, Holandsko, 1624 NP
- GSK Investigational Site
-
-
-
-
-
Bellville, Jižní Afrika, 7531
- GSK Investigational Site
-
Mowbray, Jižní Afrika, 7700
- GSK Investigational Site
-
-
Gauteng
-
Cape Town, Gauteng, Jižní Afrika, 7505
- GSK Investigational Site
-
Mueckelneck, Gauteng, Jižní Afrika, 0001
- GSK Investigational Site
-
Parktown, Gauteng, Jižní Afrika, 2193
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N1
- GSK Investigational Site
-
-
Newfoundland and Labrador
-
Bay Roberts, Newfoundland and Labrador, Kanada, A0A 1G0
- GSK Investigational Site
-
-
Ontario
-
Mississauga, Ontario, Kanada, L5A 3V4
- GSK Investigational Site
-
Ottawa, Ontario, Kanada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M5G 1N8
- GSK Investigational Site
-
-
Quebec
-
Saint Romuald, Quebec, Kanada, G6W 5M6
- GSK Investigational Site
-
Sainte Jerome, Quebec, Kanada, J7Z 5T3
- GSK Investigational Site
-
Sainte-Foy, Quebec, Kanada, G1V 4G5
- GSK Investigational Site
-
-
-
-
-
Seoul, Korejská republika, 152-703
- GSK Investigational Site
-
Seoul, Korejská republika, 133--792
- GSK Investigational Site
-
-
-
-
-
Balassagyarmat, Maďarsko, 2660
- GSK Investigational Site
-
Budapest, Maďarsko, 1095
- GSK Investigational Site
-
Budapest, Maďarsko, H-1529
- GSK Investigational Site
-
Mátraháza, Maďarsko, 3233
- GSK Investigational Site
-
-
-
-
-
Berlin, Německo, 14057
- GSK Investigational Site
-
Berlin, Německo, 10117
- GSK Investigational Site
-
Berlin, Německo, 10717
- GSK Investigational Site
-
Berlin, Německo, 10787
- GSK Investigational Site
-
Berlin, Německo, 10559
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Wiesloch, Baden-Wuerttemberg, Německo, 69168
- GSK Investigational Site
-
-
Hessen
-
Gelnhausen, Hessen, Německo, 63571
- GSK Investigational Site
-
-
Niedersachsen
-
Hannover, Niedersachsen, Německo, 30159
- GSK Investigational Site
-
Hannover, Niedersachsen, Německo, 30167
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Německo, 01307
- GSK Investigational Site
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Německo, 39112
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Německo, 23552
- GSK Investigational Site
-
-
Thueringen
-
Schmoelln, Thueringen, Německo, 04626
- GSK Investigational Site
-
-
-
-
-
Brasov, Rumunsko, 500112
- GSK Investigational Site
-
Bucharest, Rumunsko, 020125
- GSK Investigational Site
-
Iasi, Rumunsko, 700115
- GSK Investigational Site
-
-
-
-
-
London, Spojené království, SE5 9PJ
- GSK Investigational Site
-
Norwich, Spojené království, NR4 7UY
- GSK Investigational Site
-
-
Sussex East
-
Brighton, Sussex East, Spojené království, BN2 5BE
- GSK Investigational Site
-
-
-
-
Alabama
-
Jasper, Alabama, Spojené státy, 35501
- GSK Investigational Site
-
-
Arizona
-
Glendale, Arizona, Spojené státy, 85306
- GSK Investigational Site
-
-
California
-
Fountain Valley, California, Spojené státy, 92708
- GSK Investigational Site
-
Fullerton, California, Spojené státy, 92835
- GSK Investigational Site
-
Los Angeles, California, Spojené státy, 90095
- GSK Investigational Site
-
Los Angeles, California, Spojené státy, 90048
- GSK Investigational Site
-
Riverside, California, Spojené státy, 92506
- GSK Investigational Site
-
Roseville, California, Spojené státy, 95661
- GSK Investigational Site
-
San Diego, California, Spojené státy, 92103-8415
- GSK Investigational Site
-
-
Florida
-
Brandon, Florida, Spojené státy, 33511
- GSK Investigational Site
-
Panama City, Florida, Spojené státy, 32405
- GSK Investigational Site
-
South Miami, Florida, Spojené státy, 33143
- GSK Investigational Site
-
-
Idaho
-
Coeur d'Alene, Idaho, Spojené státy, 83814
- GSK Investigational Site
-
-
Kentucky
-
Madisonville, Kentucky, Spojené státy, 42431
- GSK Investigational Site
-
-
Louisiana
-
Lafayette, Louisiana, Spojené státy, 70503
- GSK Investigational Site
-
Sunset, Louisiana, Spojené státy, 70584
- GSK Investigational Site
-
-
Missouri
-
Saint Charles, Missouri, Spojené státy, 63301
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28207
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29406-7108
- GSK Investigational Site
-
Greenville, South Carolina, Spojené státy, 29615
- GSK Investigational Site
-
Spartanburg, South Carolina, Spojené státy, 29303
- GSK Investigational Site
-
Union, South Carolina, Spojené státy, 29379
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- GSK Investigational Site
-
-
Virginia
-
Abingdon, Virginia, Spojené státy, 24210
- GSK Investigational Site
-
Richmond, Virginia, Spojené státy, 23229
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thajsko, 10700
- GSK Investigational Site
-
Chiangmai, Thajsko, 50200
- GSK Investigational Site
-
Khon Kaen, Thajsko, 40002
- GSK Investigational Site
-
Songkla, Thajsko, 90110
- GSK Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- A signed and dated written informed consent prior to study participation.
- Male or female adults.
A female is eligible to enter and participate in this study if she is of:
non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is post-menopausal; or child-bearing potential, has a negative pregnancy test at Visit 1/Visit 1A, and agrees to one of the protocol-specified acceptable contraceptive methods used consistently and correctly (i.e. according to the approved product label and the instructions of the physician for the duration of the study - Screening through follow-up contact)
- 40 to 80 years of age at Visit 1
- An established clinical history of COPD
- Current or previous cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years 1.
- A post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 and a post-albuterol/salbutamol FEV1 of ≥35 and ≤70% of predicted normal values
Exclusion Criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
- Women who are pregnant or lactating.
- A current diagnosis of asthma.
- Known respiratory disorders other than COPD including but not limited to α-1 antitrypsin deficiency as the underlying cause of COPD, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, and interstitial lung disease.
- Any previous lung resection surgery (e.g., lung volume reduction surgery or lobectomy)
- Clinically significant Chest X-ray or computed tomography (CT) scan abnormalities within 6 months prior to Visit 1 that are not believed to be due to COPD.
- Use of oral corticosteroids or antibiotics for COPD within 6 weeks prior to Visit 1.
- Hospitalization for COPD or pneumonia within 3 months prior to Visit 1.
- Use of antibiotics for a lower respiratory tract infection within 30 days prior to Visit 1.
- Clinically significant and uncontrolled cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities.
- An abnormal and clinically significant 12-lead electrocardiogram (ECG) that results in active medical problem.
- Positive for Hepatitis B or Hepatitis C at Visit 1.
- A current malignancy or previous history of cancer in remission for <5 years prior to Visit 1
- A history of allergy or hypersensitivity to ipratropium, tiotropium, or atropine and any of their derivatives, lactose/milk protein or magnesium stearate.
- Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the study investigator would prevent use of an inhaled anticholingeric.
- Medically unable to withhold albuterol/salbutamol for 6 hours prior to spirometry testing at each study visit or to withhold ipratropium (if applicable) for the 6-hour period prior to the first 3 study visits (ipratropium cannot be used after Visit 3).
- Additional Medications: Unable to stop using certain medications such as bronchodilators and corticosteroids for the protocol-specified times prior to Visit 1 (the Investigator will discuss the specific medications)
- Use of inhaled corticosteroids at a dose greater than 1000 mcg/day of fluticasone propionate or equivalent within 30 days prior to Visit 1.
- Use of long-term oxygen therapy (LTOT) or supplemental oxygen required for greater than 12 hours a day. Oxygen use as needed is not exclusionary.
- Clinically significant sleep apnea that requires continuous positive airway pressure (CPAP)
- Use of regular nebulized therapy
- Use of nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV)
- Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.
- An investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the above who is involved in this study
- History of psychiatric disease, intellectual deficiency, poor motivation, substance abuse in the two years prior to Visit 1 (including drug and alcohol), or other conditions, which will limit the validity of informed consent to participate in the study.
- Use of GSK233705B in previous studies.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Arm 1
GSK233705 12.5mcg
|
Once daily via dry powder inhaler
|
Experimentální: Arm 2
GSK233705 25mcg
|
once daily via dry powder inhaler
|
Experimentální: Arm 3
GSK233705 50mcg
|
Once daily via dry powder inhaler
|
Experimentální: Arm 4
GSK233705 100mcg
|
Once daily via dry powder inhaler
|
Experimentální: Arm 5
GSK233705 200mcg
|
Once daily via dry powder inhaler
|
Komparátor placeba: Arm 6
Placebo
|
Once daily via dry powder imhaler
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29
Časové okno: Baseline (pre-dose Day 1) and Day 29
|
The trough FEV1 is defined as the mean of the FEV1 values obtained 23 and 24 hours after dosing on Day 28.
The Baseline FEV1 is the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose [time 0] on Day 1. Change from Baseline was calculated by subtracting the post-baseline assessment value from the Baseline value.
|
Baseline (pre-dose Day 1) and Day 29
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change From Baseline in Weighted Mean for 0 to 24 Hours Serial FEV1 on Day 1 to 2 and 28 to 29
Časové okno: Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Weighted means serial FEV1 was derived by calculating the area under curve (AUC), and then dividing by the time interval over which the AUC was calculated.
Baseline was defined at pre-dose Day 1.
The weighted mean change from Baseline is the weighted mean minus Baseline.
The AUC was calculated using the trapezoidal rule.
For all post-dose observations, actual times that the spirometry measurements were conducted was used for the calculation.
Pre-dose observations were counted as 0 hr observations - that is they had their time set to the time of dosing.
The pre-dose value used for the calculation of the AUC was the mean of the two pre-dose observations (-30 and 0 min for Day 1 or 28).
If one of these observations was missing, the remaining single pre-dose observation was used.
|
Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Change From Baseline in Weighted Mean for 0 to 24 Hours Forced Vital Capacity (FVC) on Day 1 to 2 and 28 to 29
Časové okno: Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Weighted means serial FVC was derived by calculating the AUC, and then dividing by the time interval over which the AUC was calculated.
Baseline was defined at pre-dose Day 1.
The weighted mean change from Baseline is the weighted mean minus Baseline.
The AUC was calculated using the trapezoidal rule.
For all post-dose observations, actual times that the spirometry measurements were conducted was used for the calculation.
Pre-dose observations were counted as 0 hr observations - that is they had their time set to the time of dosing.
The pre-dose value used for the calculation of the AUC was the mean of the two pre-dose observations (-30 and 0 min for Day 1 or 28).
If one of these observations was missing, the remaining single pre-dose observation was used.
|
Baseline (pre-dose Day 1) and Days 1 to 2, Days 28 to 29
|
Change From Baseline in Clinic Visit Trough FVC on Day 29
Časové okno: Baseline (pre-dose Day 1) and Day 29
|
The trough FVC is defined as the mean of the FVC values obtained 23 and 24 hours after dosing on Day 28.
The Baseline FVC is the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose [time 0] on Day 1. Change from Baseline was calculated by subtracting the post-baseline assessment value from the Baseline value.
|
Baseline (pre-dose Day 1) and Day 29
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- AC2110664
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Studijní data/dokumenty
-
Formulář komentované zprávy o případu
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Protokol studie
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Zpráva o klinické studii
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Plán statistické analýzy
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Soubor dat jednotlivých účastníků
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Specifikace datové sady
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulář informovaného souhlasu
Identifikátor informace: AC2110664Komentáře k informacím: For additional information about this study please refer to the GSK Clinical Study Register
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na GSK233705 12.5mcg
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníSpojené státy
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníSpojené království
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníJaponsko
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníBelgie, Švédsko
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníSpojené království
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníNěmecko
-
GlaxoSmithKlineDokončenoPlicní onemocnění, chronická obstrukčníNěmecko, Holandsko, Finsko, Ruská Federace, Spojené království